Oxbryta Product Registry (Sickle Cell Disease) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about the effects of the prescription drug Oxbryta (voxelotor) on sickle cell disease (SCD) when it is prescribed to patients. We want to keep track of the health of people with SCD who take this drug as part of their normal care.

What is the Condition Being Studied?

Sickle Cell Disease

Who Can Participate in the Study?

Adults and children who:

  • Are diagnosed with SCD
  • Started taking Oxbryta within the past 6 months or plan to begin taking Oxbryta in the future

For more information about this study, please contact the study team at stephanie.padrick@duke.edu.

Age Group
Adults, Children

What is Involved?

If you choose to join this study, you will:

  • Fill out surveys about every 6 months during your regularly scheduled hematology visits
  • Give us permission to collect information from your medical records for research

Participation in this study will last up to 5 years. We will collect information related to your health for one year or less before you begin taking Oxbryta if you do not use it when you join the study, and we will collect information related to your health for up to 5 years while you are taking Oxbryta.

Study Details

Full Title
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Principal Investigator
Protocol Number
IRB: PRO00108604
Phase N/A
Enrollment Status
Open for Enrollment